DexComvs.Eli Lilly
DXCM vs LLY · both in Diabetes & metabolic disease, part of the Medicine, pharma & life science value chain: Treatment and monitoring of diabetes and metabolic disease, from insulin to glucose monitoring.
Eli Lilly is about 34× larger than DexCom by market cap; DexCom trades at the lower P/E (31.8 vs 41.0); year to date, DexCom leads (+27.0% vs +10.6%).
Side by side
| DXCM | LLY | |
|---|---|---|
| Market cap | $31.8B | $1.1T |
| Price | $84.41 | $1,169.60 |
| Today | +0.1% | −1.6% |
| Return YTD | +27.0% | +10.6% |
| Return 1Y | +27.7% | +40.9% |
| Since June 26, 2026 | +20.3% | −3.2% |
| P/E | 31.8 | 41.0 |
| P/S | 6.4 | 13.8 |
| P/B | 12.1 | 32.3 |
Data as of 2026-10-08 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
DexComDXCM
Continuous glucose monitoring for people with diabetes: the G-series sensors, and Stelo, which is sold over the counter.
Full DXCM profile →Eli LillyLLY
Mounjaro and Zepbound put Lilly at the centre of the GLP-1 market. Around them sit the diabetes and insulin business and franchises in oncology and neurology, with a pipeline that ranks among the strongest in the industry.
Full LLY profile →More DXCM & LLY comparisons
Other head-to-heads in the Diabetes & metabolic disease segment.